Recent market activity indicates a significant surge in mergers and acquisitions within the biopharma sector, a trend that could see increasing private equity involvement, as speculated by Pearl Freier. This comes as a clarification emerges regarding a recent retail transaction, where Everlane was not directly sold to Shein by a private equity firm, as initially suggested in a social media post.
Pearl Freier's tweet, stating, > "I saw this news about Everlane being sold off by its private equity firm to Shein & I wondered if we'll see more of this in biotech over the next few years," highlighted a perceived trend of private equity-led divestitures to strategic buyers. However, the actual transaction involved SPARC Group acquiring Everlane in 2023. Shein later took a minority stake in SPARC Group in August 2023, making it a strategic partner to the group that owns Everlane, rather than a direct acquisition of Everlane itself.
Despite the nuance in the retail example, Freier's underlying question about increased M&A in biotech appears well-founded. The biopharma sector experienced a substantial rebound in M&A activity in 2023, with aggregate deal value climbing by 79% compared to 2022, reaching approximately $152 billion. This momentum is projected to continue, with forecasts suggesting deal values could hit $180-$200 billion in 2024, according to industry reports.
Several factors are fueling this robust M&A environment in biotech. Pharmaceutical giants are facing a looming "patent cliff," with an estimated $210-$250 billion in revenue at risk from patent expirations by 2030 in the U.S. alone. This creates an urgent need for large pharmaceutical companies to acquire innovative assets to replenish their pipelines and drive future growth. Emerging Biopharma Companies (EBPs) continue to be a primary source of innovation, and while their funding environment is improving, many still look to M&A as a viable exit strategy.
Private equity firms are playing an active role in the life sciences M&A landscape, often focusing on middle-market deals and corporate divestitures. The year 2023 also saw a notable rise in "take-private" transactions by PE firms, where public life sciences companies were acquired and delisted. Acquirers are increasingly prioritizing de-risked assets, with 74% of 2023 transactions focusing on targets in Phase 3 clinical trials or already on the market.
While oncology remains a leading area for deals, significant interest is also observed in central nervous system (CNS) disorders and cardiometabolic conditions, particularly those related to obesity, driven by the success of GLP-1 therapies. The broader M&A market is characterized by "megadeals" exceeding $5 billion, with AI becoming a critical catalyst, influencing strategic rationales and capital allocation decisions across industries, including biopharma. This dynamic environment suggests that Freier's anticipation of increased M&A activity in biotech is aligned with current market trends, driven by strategic imperatives and a shifting investment landscape.
